Crohn's Disease News and Research

Latest Crohn's Disease News and Research

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has granted Fast Track Designation to TxCell’s lead product Ovasave for the treatment of moderate to severe Crohn’s disease.

28 Jul 2015

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information.

24 Jul 2015

Study shows regions of genome underlying IBD consistent around the world

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted under the auspices of the International IBD Genetics Consortium, included nearly 10,000 DNA samples from people of East Asian, Indian or Iranian descent and an existing set of 86,640 samples drawn from across Europe, North America and Oceania.

22 Jul 2015

Biosimilars show promise for children with IBD, but more research needed

Children with inflammatory bowel disease (IBD) who are doing well on specific biological medications should not be switched to recently approved "biosimilar" products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.

14 Jul 2015

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma AG, part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca.

9 Jul 2015

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

In a new study of more than 125,000 pregnant women in Sweden, researchers found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

9 Jul 2015

Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

A technology whose roots date to the 1800s has the potential to offer an extraordinary new advantage to modern-day medicine.

9 Jul 2015

Common arthritis drug could help to treat patients with blood cancers

Scientists at the University of Sheffield have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers.

7 Jul 2015

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms.

1 Jul 2015

Exhausted army of immune cells may damage the very body they are supposed to protect

An 'exhausted' army of immune cells may not be able to fight off infection, but if its soldiers fight too hard they risk damaging the very body they are meant to be protecting, suggests new research from the University of Cambridge.

30 Jun 2015

$FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease$

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease.

30 Jun 2015

Study opens up new line of research into origin of digestive diseases

There are numerous studies related to the absorption of nutrients from the stomach since understanding what happens in our digestive system is crucial, for example, in order to be able to avoid in the future some of the diseases that affect part of the population to a lesser or greater extent.

29 Jun 2015

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.

25 Jun 2015

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will provide an oral presentation on an abstract related to the company's lead product candidate, AMG 714, at the 16th International Coeliac Disease Symposium, June 24, 2015, in Prague, Czech Republic.

22 Jun 2015

Vitamin D supplementation may treat Crohn’s disease

New research published in this month’s edition of United European Gastroenterology Journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn’s disease, and could have a role in the treatment of the condition.

15 Jun 2015

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

New research published in this month's edition of United European Gastroenterology journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn's disease, and could have a role in the treatment of the condition.

13 Jun 2015

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.

10 Jun 2015

Non-invasive accupoint electrical stimulation to treat Crohn's disease

An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.

10 Jun 2015

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

Hospira, Inc., a global leader in biosimilars, today announced that its partner, Celltrion – a global biopharmaceutical company – has received approval from ANVISA – the National Health Surveillance Agency in Brazil – for Remsima (infliximab), the first biosimilar monoclonal antibody approved for use in Brazil.

2 Jun 2015

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

Clinical experience of biosimilar infliximab in 78 inflammatory bowel disease (IBD) patients presented at Digestive Diseases Week (DDW) 2015 in Washington D.C. showed that the treatment is comparable to the reference medicinal product (RMP) in terms of efficacy and safety.

20 May 2015

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

Study shows regions of genome underlying IBD consistent around the world

Biosimilars show promise for children with IBD, but more research needed

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Risk of hepatobiliary cancer, cardiovascular diseases later in life is higher in women with ICP

Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

Common arthritis drug could help to treat patients with blood cancers

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Exhausted army of immune cells may damage the very body they are supposed to protect

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

Study opens up new line of research into origin of digestive diseases

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Celimmune to provide oral presentation on AMG 714 antibody at 16th International Coeliac Disease Symposium

Vitamin D supplementation may treat Crohn’s disease

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Non-invasive accupoint electrical stimulation to treat Crohn's disease

Celltrion receives approval for infliximab biosimilar antibody from Brazil's ANVISA

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in